Mounjaro (tirzepatide) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist
Research into the area is far from complete
Current evidence consistently supports associations with common symptoms such as nausea, vomiting, diarrhea, and constipation, whereas links to more serious complications including pancreatitis, gastroparesis, or intestinal obstruction remain weak or inconsistent
A graduate of the College of William and Mary and the master's program at the Missouri School of Journalism, she ...
It is a first-in-class triple hormone receptor agonist, designed as a single molecule that simultaneously activates three distinct receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon (GCG)
The magnitude of weight change observed in some DIO studies appeared to exceed that reported for GLP-1R single agonists under comparable conditions in the same model systems [VERIFY]